GlassScriptPhysician profile
Nicole Valeria Munteanu
NPI 1639996614
$1,980.97
in general payments reported to CMS, 2019-2025
35 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $211 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291.43 | 2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $151.33 | 2025 | Andembry, Hizentra |
| Genentech USA, INC. | $143.61 | 2024-2025 | Phesgo, Itovebi, Xolair |
| Organon LLC | $135.33 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $105.68 | 2025 | Dupixent |
| Janssen Biotech, INC. | $95.89 | 2025 | Darzalex, Tecvayli, Talvey |
| Optinose US, INC. | $83.08 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $66.37 | 2024-2025 | Krazati, Opdivo |
| Adc Therapeutics America, INC. | $61.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $61.34 | 2025 | |
| Servier Pharmaceuticals LLC | $59.19 | 2025 | |
| Ionis Pharmaceuticals, INC. | $53.29 | 2025 | Dawnzera |
| Takeda Pharmaceuticals U.S.A., INC. | $51.44 | 2025 | Eohilia, Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.71 | 2024-2025 | Gilotrif |
| Paratek Pharmaceuticals, INC. | $42.25 | 2025 | Xhance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $41.81 | 2025 | Amtagvi |
| Pfizer INC. | $40.64 | 2025 | |
| Incyte Corporation | $38.70 | 2024-2025 | Jakafi |
| Ars Pharmaceuticals Operations, INC. | $38.19 | 2025 | Neffy |
| Agios Pharmaceuticals, INC. | $36.76 | 2024 | Pyrukynd |
| Glaxosmithkline, LLC. | $35.93 | 2025 | Nucala, Trelegy Ellipta |
| Octapharma USA, INC. | $31.78 | 2025 | Octagam Immune Globulin (Human) |
| Legend Biotech USA INC. | $27.26 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $24.77 | 2024 | Tavalisse, Rezlidhia |
| Abbvie INC. | $24.37 | 2025 | |
| Biocryst US Sales Co., LLC | $23.46 | 2025 | Orladeyo |
| Leo Pharma INC. | $23.27 | 2025 | Anzupgo |
| Sobi, INC | $23.22 | 2025 | |
| Astellas Pharma US INC | $21.30 | 2024 | Padcev |
| Daiichi Sankyo INC. | $19.11 | 2025 | Injectafer |
| Exelixis INC. | $18.55 | 2025 | Cabometyx |
| Emd Serono, INC. | $17.72 | 2025 | |
| Gilead Sciences, INC. | $17.44 | 2024 | Trodelvy |
| Genzyme Corporation | $16.87 | 2025 | |
| Aveo Pharmaceuticals, INC. | $14.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Munteanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.